Last reviewed · How we verify
B arm (DAC)
DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis.
DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis. Used for Acute myeloid leukemia (AML) in adult patients.
At a glance
| Generic name | B arm (DAC) |
|---|---|
| Also known as | Daunorubicin, Cladribine, Cytarabine |
| Sponsor | Polish Adult Leukemia Group |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This triplet combination uses daunorubicin as a topoisomerase II inhibitor and intercalating agent, cytarabine as a nucleoside analog that disrupts DNA synthesis, and cladribine as a purine analog that accumulates in leukemic cells. Together, these agents work synergistically to kill rapidly dividing leukemic blasts through multiple mechanisms of DNA damage and cell cycle arrest.
Approved indications
- Acute myeloid leukemia (AML) in adult patients
Common side effects
- Myelosuppression / neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Mucositis
- Nausea and vomiting
- Cardiotoxicity
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (PHASE1, PHASE2)
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission (PHASE1)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B arm (DAC) CI brief — competitive landscape report
- B arm (DAC) updates RSS · CI watch RSS
- Polish Adult Leukemia Group portfolio CI